- Home
- IDYA vs BATRA Comparison
IDYA vs BATRA Comparison
Compare IDYA & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- BATRA
- Stock Information
- Founded
- IDYA 2015
- BATRA 1991
- Country
- IDYA United States
- BATRA United States
- Employees
- IDYA N/A
- BATRA N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- BATRA Broadcasting
- Sector
- IDYA Health Care
- BATRA Industrials
- Exchange
- IDYA Nasdaq
- BATRA Nasdaq
- Market Cap
- IDYA 1.9B
- BATRA 2.6B
- IPO Year
- IDYA 2019
- BATRA N/A
- Fundamental
- Price
- IDYA $22.10
- BATRA $50.00
- Analyst Decision
- IDYA Strong Buy
- BATRA Strong Buy
- Analyst Count
- IDYA 13
- BATRA 3
- Target Price
- IDYA $53.42
- BATRA $58.00
- AVG Volume (30 Days)
- IDYA 1.0M
- BATRA 83.9K
- Earning Date
- IDYA 08-05-2025
- BATRA 08-07-2025
- Dividend Yield
- IDYA N/A
- BATRA N/A
- EPS Growth
- IDYA N/A
- BATRA N/A
- EPS
- IDYA N/A
- BATRA N/A
- Revenue
- IDYA $7,000,000.00
- BATRA $672,879,000.00
- Revenue This Year
- IDYA $101.20
- BATRA $8.81
- Revenue Next Year
- IDYA $286.70
- BATRA $5.01
- P/E Ratio
- IDYA N/A
- BATRA N/A
- Revenue Growth
- IDYA N/A
- BATRA 4.04
- 52 Week Low
- IDYA $13.45
- BATRA $38.67
- 52 Week High
- IDYA $44.42
- BATRA $50.00
- Technical
- Relative Strength Index (RSI)
- IDYA 58.95
- BATRA 64.68
- Support Level
- IDYA $20.50
- BATRA $48.11
- Resistance Level
- IDYA $22.27
- BATRA $50.00
- Average True Range (ATR)
- IDYA 0.94
- BATRA 1.03
- MACD
- IDYA -0.13
- BATRA 0.08
- Stochastic Oscillator
- IDYA 70.88
- BATRA 76.37
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About BATRA Atlanta Braves Holdings Inc. Series A
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.